Nested Therapeutics Announces Nomination of First Developmen

Nested Therapeutics Announces Nomination of First Development Candidate, a Potential First-in-Class Inhibitor of the RAS/MAPK Pathway

/PRNewswire/ -- Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today...

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Klaus Hoeflich , , Darrin Miles , Chief Executive Officer , Chief Scientific Officer , Nested Therapeutics , Nc ,